Here, we describe how to efficiently direct human pluripotent stem cells (hpscs) differentiation into self-renewing epicardial cells in a completely defined, xeno-free system by temporal modulation of regulators of canonical Wnt signaling. appropriate differentiation-stage-specific application of Gsk3 inhibitor, Wnt inhibitor, and Gsk3 inhibitor (GiWiGi) is sufficient to produce cells expressing epicardial markers and exhibiting epicardial phenotypes with a high yield and purity from multiple hpsc lines in 16 d. characterization of differentiated cells is performed via flow cytometry and immunostaining to assess quantitative expression and localization of epicardial cell-specific proteins. In vitro differentiation into fibroblasts and smooth muscle cells (sMcs) is also described. In addition, culture in the presence of transforming growth factor (tGF)-b inhibitors allows long-term expansion of hpsc-derived epicardial cells (for at least 25 population doublings). Functional human epicardial cells differentiated via this protocol may constitute a potential cell source for heart disease modeling, drug screening, and cell-based therapeutic applications.
IntroDuctIon
hPSCs, including human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), possess enormous potential for the study and treatment of cardiovascular diseases because of their capacity for unlimited self-renewal and ability to form any somatic cell type 1, 2 . Functional epicardial cells and their progeny differentiated from hPSCs could be beneficial for many applications, including cardiac disease modeling, drug discovery, and cellular therapies 3 . Realization of this potential will require protocols to differentiate hPSCs to cardiovascular cell lineages with high efficiency and reproducibility in a scalable and cost-effective manner. Moreover, therapeutic applications necessitate defined, xeno-free cell-manufacturing processes.
Over the past decade, there has been substantial progress in the generation of cardiomyocytes [4] [5] [6] [7] [8] , endothelial cells [9] [10] [11] [12] [13] , and SMCs [14] [15] [16] from hPSCs. However, there have been only a few reports describing the differentiation of hPSCs into epicardial cells. Epicardial cells have been shown to contribute to fibroblast, smooth muscle, and vascular endothelial cell compartments in the developing heart, and they also secrete trophic and regulatory factors involved in heart development and maintenance 17, 18 . Initial efforts to differentiate hPSCs into epicardial cells implemented stage-specific application of BMP and Wnt ligands to embryoid bodies (EBs) 19 . In this approach 19 , treatment of EBs with BMP4 for 1 d and then with BMP4, activin A, and basic fibroblast growth factor (bFGF) for 3 d induced mesoderm differentiation. The EBs were plated and treated with DKK1, VEGF, and SB431542 for 2 d to stimulate cardiovascular specification. Addition of BMP4 during this stage resulted in epicardial differentiation. Iyer et al. 20 demonstrated differentiation of hPSCs into epicardial cells with a purity of at least 60% in multiple hPSC lines via a monolayer-based differentiation method. hPSCs treated with bFGF, Ly294002, and BMP4 for 36 h formed early mesoderm. An additional 3.5 d of bFGF and BMP4 treatment resulted in formation of lateral plate mesoderm, which was then directed to epicardium by 10 d of treatment with BMP4, Wnt3a, and retinoic acid. These seminal studies pioneered efforts to differentiate hPSCs into epicardial cells, but the inclusion of expensive growth factors and/or xenogenic components in these protocols limits largescale production and therapeutic applications. Furthermore, these hPSC-derived epicardial cells dedifferentiated in culture, similar to primary human epicardial cells 21 , complicating manufacturing and further applications.
To address these issues, we used a WT1-2A-eGFP knock-in hPSC line to show that temporal modulation of canonical Wnt signaling by small molecules is sufficient for epicardial induction from hPSCs under chemically defined, xeno-free conditions, and that TGF-β inhibitor treatment permits long-term expansion of hPSC-derived epicardial cells 22 . After 48 d of expansion, the hPSCderived epicardial cells exhibited uniform expression of epicardial markers and retained the capacity to differentiate into fibroblasts and SMCs. The majority of the hPSC-derived WT1 + /TBX18 + cells also expressed TCF21, suggesting that this differentiation protocol might generate a subset of WT1 + cells identified in human epicardial cultures 20 , as well as in chick and mouse epicardium 23 . By contrast, Iyer et al. 20 reported populations of WT1 + /TCF21 + , WT1 + /TCF21 − , WT1 − /TCF21 + , and WT1 − /TCF21 − cells in their epicardial differentiation cultures. Differences between our study and the Iyer et al. report, including the starting cardiac progenitor cells (CPCs) and exposure to different developmental pathway modulators, may account for the generation of a more homogeneous subpopulation of epicardium in our protocol. These findings improve our understanding of epicardial cell specification and self-renewal, and they have implications for the generation of human epicardial cells for therapeutic applications.
In this protocol, we provide a detailed step-by-step process for 2D monolayer-based direct differentiation of hPSCs into epicardial cells. This protocol uses a completely defined, growth-factorfree and xeno-free system, and applies temporal modulation of Wnt/β-catenin signaling via small molecules. This protocol is based on our earlier reports of cardiac progenitor and epicardial differentiation 5, 22 . It builds on the hPSC culture steps described in our earlier GSK3 inhibitor and Wnt inhibitor (GiWi) cardiomyocyte differentiation protocol 6 and advances in xeno-free production of Isl1 + Nkx2.5 + cardiac progenitor molecules used in our GiWi2 method 5 . The present protocol is composed of four major stages: induction of cardiac progenitors from hPSCs by temporal modulation of canonical Wnt signaling under defined, albumin-free conditions (Steps 1-8), directed differentiation of cardiac progenitors to proepicardial and then to epicardial cells by Gsk3 inhibitor treatment (Steps 9-14), long-term maintenance of hPSC-derived epicardial cells under chemically defined conditions in the presence of a TGF-β inhibitor (Step 15A-C), and in vitro differentiation of epicardial cells to fibroblasts and SMCs (Step 15D). This protocol will enable efficient production of human epicardial cells for development and disease research, drug screening and testing, and advancement of cardiac cellular therapies.
Experimental design Induction of cardiac progenitors from hPSCs (Steps 1-8).
A summary of cardiac progenitor generation (GiWi2 protocol 5 ) is shown in Figure 1 . The hPSCs are initially cultured on Matrigel-coated plates or Synthemax-coated plates in mTeSR1 or E8 medium until fully confluent. For translational applications in which fully defined differentiation is important, a combination of Synthemax and E8 is recommended. The starting hPSC population should contain at least 95% Oct4 + cells with no detectable karyotypic abnormalities. Differentiation is initiated by removing the maintenance medium and adding the RPMI basal medium containing a Gsk3 inhibitor such as CHIR99021. Culturing for 24 h in this medium generates a high percentage of brachyuryexpressing cells (>95% by flow cytometry) (Fig. 1) . To direct these brachyury-expressing mesendoderm progenitor cells to a cardiac progenitor fate, inhibition of canonical Wnt signaling by Wnt signaling inhibitors, such as porcupine inhibitors IWP2 or IWP4, is performed on day 3. On days 5 and 6, this approach generates Nkx2.5 + Isl1 + CPCs under chemically defined, albumin-free differentiation conditions. The CPCs can also be efficiently generated in albumin-containing RPMI/B27 minus insulin medium with 12 µM CHIR99021 using our previous GiWi protocol 6 .
Directed differentiation of cardiac progenitors into proepicardial and epicardial cells (Steps 9-14)
. A summary of this directed differentiation protocol is shown in Figure 2 . On day 6, hPSC-derived CPCs are singularized and seeded onto gelatin-or Synthemax-coated plates in albumin-containing LaSR 13 basal medium (Advanced DMEM/F12 with 2.5 mM GlutaMAX and 100 µg/ml ascorbic acid) or albumin-free RPMI/Vc/Ins medium (100 µg/ml ascorbic acid and 1 µg/ml insulin), as needed. When cultured in these media without any treatment, the CPCs will spontaneously differentiate into functional contracting cardiomyocytes 22 . To direct these Nkx2.5 + Isl1 + CPCs to an epicardial cell fate, activation of canonical Wnt signaling by Gsk3 inhibitors such as CHIR99021 is performed for 48 h from day 7 to day 9. WT1 + TBX18 + epicardial cells are obtained on day 12 when cultured in LaSR basal or RPMI/Vc/Ins medium for another 3 d. Epicardial cell differentiation proceeds rapidly, and WT1 can be readily detected on day 10 of differentiation. The purity of WT1 + cells on day 12 should be >90% (Fig. 2) . At day 12, the population consists of WT1 + /ALDH1A2 − proepicardial cells, but, by day 16, these cells express ALDH1A2 and upregulate tight junction protein ZO-1 to become epicardial cells.
Long-term maintenance of hPSC-derived epicardial cells (
Step 15A-C). A summary of the maintenance protocol is shown in Figure 3 . To expand these hPSC-derived epicardial cells, confluent cells on days 12-16 after initiation of differentiation or on day 4
after passage are split in a 1:3 to 1:9 ratio using either Versene or Accutase (Fig. 3) . Although Versene and Accutase work similarly at early passages, we found that Versene passaging leads to more efficient expansion of the epicardial cells after eight passages. When cultured in LaSR basal medium without any treatment, these cells will spontaneously undergo epithelial-mesenchymal transition to form smooth muscle-like cells after two or three passages. Therefore, to promote cell self-renewal, a TGF-β inhibitor (e.g., A83-01 or SB431542) is added to the culture medium, resulting in long-term self-renewing epicardial cells. Even after 2 months and 25 doublings in LaSR basal medium, these cells still retain the molecular markers and morphological and functional characteristics of primary epicardial cells (Figs. 4 and 5) . hPSC-derived epicardial cells can also be maintained for ~24 d in albumin-free RPMI/Vc/Ins medium. Step 15B). Epicardial cells were generated from H13 hESCs as described in Figure 2 and were maintained as described in Figure 3 . On day 48, cells were individualized and replated on 0.1% gelatin-coated coverslips. Immunostaining for β-catenin, WT1, ZO1, K18, E-cadherin (E-cad), TBX18, TCF21, and ALDH1A2 are shown. The antibodies used are given in table 1. Scale bars, 50 µm. basal medium supplemented with 5 µM Y-27632 (Fig. 3) . After 24 h, the medium is changed to LaSR basal medium and treated with bFGF or/and TGF-β1 for 6 d. bFGF-treated cells adopt a fibroid spindle-like morphology typical of cultured fibroblasts, whereas TGF-β1-or TGF-β1+bFGF-treated cells display a fusiform appearance typical of SMCs (Fig. 6b) . The expression of calponin and smooth muscle myosin heavy chain (SMMHC) in TGF-β1-induced cultures further supports their SMC identity, and vimentin (VIM) and CD90 expression supports their fibroblast identity. These hPSC-derived epicardial cells have also been shown to have the capacity to generate endothelial cells at low efficiency 24 . Filter the medium with a 500-ml Stericup filtration system. The medium can be stored at 4 °C for up to 2 months. 1% (vol/vol) Formaldehyde Add 62.5 µl of 16% formaldehyde to 1 ml of PBS. We do not recommend storing this solution. 4% (vol/vol) Formaldehyde Add 1 ml of 16% formaldehyde to 3 ml of PBS. We do not recommend storing this solution. 90% (vol/vol) Methanol Add 5 ml of Milli-Q water to 45 ml of pure methanol. The solution can be stored at −20 °C for up to 6 months. 0.1% (wt/vol) BSA Add 1 g of BSA to 1,000 ml of PBS, and filter the solution using a Stericup filtration system. Store the solution at 4 °C for up to 6 months. A83-01 (10 mM) Add 2.37 ml of DMSO to 10 mg of A83-01. Prepare aliquots and store them at −20 °C for up to 1 year. bFGF (25 mg/ml) Add 1 ml of sterile PBS to 25 µg of bFGF. Prepare aliquots and store them at −20 °C for up to 3 months. CHIR99021 (36 mM) Add 1.49 ml of DMSO to 25 mg of CHIR99021. Prepare aliquots and store them at −20 °C for up to 1 year. CPC freezing medium (50 ml) In a sterile environment, mix 30 ml of DMEM, 15 ml of FBS, 5 ml of DMSO, and 50 µl of Y27632. The medium can be stored at 4 °C for up to 2 months. Proepicardial freezing medium (50 ml) In a sterile environment, mix 30 ml of LaSR basal medium, 15 ml of FBS, 5 ml of DMSO, 2.5 µl of A83-01, and 50 µl of Y27632. The medium can be stored at 4 °C for up to 2 months. l-Ascorbic acid (100 mg/ml) In a sterile environment, add 50 ml of sterile Milli-Q water to 5 g of l-ascorbic acid. Prepare 1-ml aliquots and store them at −20 °C for up to 1 year. LaSR basal medium (500 ml) In a sterile environment, mix 500 ml of Advanced DMEM/F12 medium, 6.5 ml of GlutaMAX, and 500 µl of 100 mg/ml ascorbic acid solution. The medium can be stored at 4 °C for up to 2 months. LaSR basal medium + 3 mM CHIR99021 (24 ml) Add 2 µl of 36 mM CHIR99021 to 24 ml of LaSR basal medium. We do not recommend storing this medium. RPMI/B27 minus insulin (510 ml) In a sterile environment, mix 500 ml of RPMI and 10 ml of B27 supplement minus insulin. The medium can be stored at 4 °C for up to 1 month.
Differentiation of hPSC-derived epicardial cells into fibroblasts and SMCs (Step 15D
)
MaterIals

REAGENTS
•
RPMI/B27 (510 ml) In a sterile environment, mix 500 ml of RPMI and 10 ml of B27 supplement. The medium can be stored at 4 °C for up to 1 month. RPMI20 (250 ml) In a sterile environment, mix 200 ml of RPMI and 50 ml of FBS, then filter through a 250-ml Stericup filtration system. The medium can be stored at 4 °C for up to 1 month. RPMI/Vc/Ins (500 ml) In a sterile environment, mix 500 ml of RPMI, 1 ml of 100 mg/ml l-ascorbic acid, and 500 µl of insulin solution.
The medium can be stored at 4 °C for up to 2 months.
RPMI/Vc/Ins + 3 µM CHIR99021 (24 ml) Add 2 µl of 36 mM CHIR99021 to 24 ml of RPMI/Vc/Ins medium. We do not recommend storing this medium. IWP2 (5 mM) Add 4.28 ml of DMSO to 10 mg of IWP2. Incubate the mixture at 37 °C for 10 min to dissolve the IWP2. Prepare 100-µl aliquots in 1.5-ml tubes, and store them at −20 °C for up to 1 year. IWP4 (5 mM) Add 0.805 ml of DMSO to 2 mg of IWP4. Incubate the mixture at 37 °C for 10 min to dissolve the IWP4. Prepare 100-µl aliquots in 1.5-ml tubes, and store them at −20 °C for up to 1 year. 
mM Y27632
In a sterile environment, add 6.24 ml of PBS to 10 mg of Y27632. Prepare 100-µl aliquots in 1.5-ml tubes, and store them at −20 °C for up to 1 year. mTeSR1 + 5 µM Y27632 Add 50 µl of 5 mM Y27632 to 50 ml of mTeSR1 (final concentration of Y27632 is 5 µM). Store the solution at 4 °C for up to 2 weeks. 0.1% (wt/vol) Gelatin (30 ml) Add 1.5 ml of 2% gelatin solution to 30 ml of sterile Milli-Q water. We do not recommend storing this solution. Flow buffer 1 (500 ml) Add 2.5 g of BSA to 500 ml of PBS, and filter the mixture using a 500-ml Stericup filtration system. The medium can be stored at 4 °C for up to 6 months. 1% (vol/vol) Triton X-100 solution (500 ml) Add 5 ml of Triton X-100 to 495 ml of PBS and shake the bottle to dissolve the Triton X-100. The medium can be stored at 4 °C for up to 6 months. Flow buffer 2 (550 ml) Add 2.5 g of BSA and 50 ml of 1% Triton X-100 solution to 500 ml of PBS, and filter the solution using a 500-ml Stericup filtration system. The medium can be stored at 4 °C for up to 6 months. 10% (vol/vol) Triton X-100 solution (50 ml) Add 5 ml of Triton X-100 to 45 ml of PBS, and shake the tube to dissolve the Triton X-100. The medium can be stored at 4 °C for up to 6 months. 5% (wt/vol) Nonfat dry milk + 0.4% (vol/vol) Triton X-100 Add 0.5 g of nonfat dry milk and 4 ml of 1% Triton X-100 solution to 6 ml of PBS. We do not recommend storing this solution. Hoechst staining solution (5 µg/ml) Add 2.5 µl of Hoechst 33342 stock solution (10 mg/ml) to 5 ml of PBS. We do not recommend storing this solution. SB431542 (10 mM) Add 2.60 ml of DMSO to 10 mg of SB431542. Prepare aliquots and store them at −20 °C for up to 1 year. Synthemax II-SC stock solution (1 mg/ml) Add 10 ml of sterile water to the vial containing 10 mg of Corning Synthemax II-SC substrate, and mix the solution well to make a homogeneous 1 mg/ml stock solution. The solution can be stored at 4 °C for up to 6 months. TGF-b1 (20 mg/ml) Add 100 µl of sterile 4 mM HCl containing 0.1% BSA to 2 µg of TGF-β1. Prepare aliquots and store the solution at −20 °C for up to 3 months. EQUIPMENT SETUP Matrigel-coated plates Matrigel-coated plates can be made according to our previous protocol 6 . Briefly, in a sterile hood, add 30 ml of cold (4 °C) DMEM/F12 to a 50-ml conical tube and keep it cold by placing it on ice. Remove one Matrigel aliquot (2.5 mg) from the freezer, and add 1 ml of cold DMEM/F12 to it. Gently pipette the Matrigel solution with a P1000 tip to thaw and dissolve the Matrigel. Immediately transfer the Matrigel solution to the 50-ml conical tube that contains 30 ml of cold DMEM/F12. Immediately add 1 ml per well of Matrigel in DMEM/F12 for 6-well plates, 0. Figure 1 . Briefly, the intact cell population, without cell debris, is gated from forward and side scatter for further analysis (Supplementary Fig. 1a ). Change the x and y parameters (in this case, 'Histogram' and 'Alexa-488') on the Graph Window to gate the cell population of interest in both isotype and primary-antibody-stained samples with a ranged tool (Supplementary Fig. 1b) . Use the 'Layout Editor' to create an overlay histogram report (Supplementary Fig. 1c ).
proceDure cardiac progenitor differentiation with Gsk3 inhibitor and Wnt inhibitor (GiWi2 protocol) • tIMInG 6 d 1|
Culture the hPSCs on Matrigel-coated or Synthemax-coated six-well plates in mTeSR1 or E8 medium to 80-90% confluence. Further details regarding feeder-independent culture of hPSCs are provided in Steps 1-6 of our previous protocol 6 . Aspirate the medium and add 1 ml of room-temperature Accutase to each well. Put the plate into a 37 °C, 5% CO 2 incubator and wait for 5 min.
2|
Add 0.5 ml of mTeSR1 or E8 to each well of the six-well plate and pool all the cells in a 15-ml conical tube. Mix them well and count the total cell number with a hemocytometer. Centrifuge the cells at 200g for 5 min at room temperature.
3|
Aspirate the supernatant, resuspend the cells in mTeSR1 or E8 + 5 µM Y27632 at a cell density of 2 million cells per ml, and plate 0.5-2.0 million cells per well in each well of a 12-well Matrigel-or Synthemax-coated plate. Add mTeSR1 or E8 + 5 µM Y27632 medium to each well to make a final volume of 1 ml in each well of the 12-well plate. This time point corresponds to day −3.  crItIcal step The starting seeding cell density is critical to efficient cardiac differentiation. The initial plating density and/or the time of expansion before initiation of differentiation may require optimization for different cell lines or expansion conditions. We recommend plating 0.5-2.0 million cells per well of a 12-well plate and expanding the cells for 3 d before initiation of differentiation.
4|
On day −2 and day −1, aspirate the medium and replace it with 2 ml of room-temperature mTeSR1 or E8 per well of the 12-well plate. For cells cultured in E8, precondition the hPSCs with 0.1-0.6 µM CHIR99021 on day −1 for cardiac differentiation.
? troublesHootInG protocol 1896 | VOL.12 NO.9 | 2017 | nature protocols 5| On day 0, prepare RPMI medium containing 6 µM CHIR99021. You will need 2 ml of RPMI for each well of the 12-well plate, so a total of 24 ml is needed to differentiate cells in all 12 wells. Add 4 µl of 36 mM CHIR99021 to 24 ml of RPMI basal medium to make RPMI medium containing 6 µM CHIR99021. Aspirate the old medium and then add 2 ml of RPMI medium containing 6 µM CHIR99021 to each well of the 12-well plate and record the time. Alternatively, Steps 5-8 can also be performed in albumin-containing RPMI/B27 medium lacking insulin, as described in Step 12B of our previous GiWi protocol 6 .  crItIcal step Recording the time when you finish adding RPMI medium containing CHIR99021 is important, as you must change the medium exactly 24 h later. Although we identified 6 µM CHIR99021 as the optimal concentration for the hPSC lines that we tested, other lines may respond to CHIR99021 treatment differently. We have also found substantial lot-to-lot variability in CHIR99021 activity. Thus, optimization of CHIR99021 concentration may be required, especially when changing lots or suppliers. We recommend testing 3-12 µM CHIR99021.
6|
On day 1, aspirate the medium from each well of the 12-well plate and replace it with 2 ml of room-temperature RPMI basal medium. Put the plate back into the 37 °C, 5% CO 2 incubator. ? troublesHootInG 7| On day 3 (72 h post addition of CHIR99021), prepare a combined medium: use a 5-ml pipette to collect 1 ml of medium from the 12-well plate, and mix it with 1 ml of freshly prepared RPMI basal medium in a 15-ml conical tube. This 2 ml of medium is called 'combined medium' . Add 1 µl of 5 mM IWP2 (final concentration is 2.5 µM) to the 2 ml of combined medium. Before aspirating, gently rock the plate back and forth to suspend any cell debris, ensuring that the cell debris will be removed after aspiration. Aspirate the remaining 1 ml of medium from each well of the 12-well plate, and then add 2 ml per well of the combined medium containing IWP2 to each well.  crItIcal step Although we identified 2.5 µM IWP2 as the optimal concentration for the hPSC lines that we tested, other lines may respond to IWP2 treatment differently. Thus, optimization of the IWP2 concentration may be required. We recommend testing 2-8 µM IWP2.
8|
On day 5, aspirate the medium from each well of the 12-well plate, and add 2 ml per well of room-temperature RPMI basal medium. Return the plate to the 37 °C, 5% CO 2 incubator.  crItIcal step Although we identified day 6 cells as the optimal starting cell population for epicardial cell generation, day 5 or 7 cells also efficiently generated WT1 + epicardial cells after 2 d of CHIR99021 treatment (days 6-8 or days 8-10). If day 5 cells are used, it is not necessary to change the medium on day 5. Instead, singularize the cells and seed according to Steps 9-12.
Directed differentiation of cardiac progenitors into proepicardial cells • tIMInG 6 d 9| On day 6 of the GiWi2 (ref. 5) or GiWi 6 protocol, aspirate the medium, add 1 ml of Accutase per well in a 12-well plate, and incubate the plate in a 37 °C, 5% CO 2 incubator for 5 min. For a quick passage without centrifugation (skipping Steps 10-12), aspirate the Accutase, gently scrape the cells with a glass pipette into the corresponding plating medium, and seed the cells at a split ratio of 1:3 to 1:12. If you have more time, however, proceed instead to Step 10.  crItIcal step Although we found that centrifugation is not necessary for cell passaging, a 5-min treatment of Accutase might dissociate the cells from the plate surface, resulting in cell loss. In that case, decrease the Accutase incubation time or use a gentler dissociating buffer (e.g., Versene).
10|
Pipette 5-10 times with a P1000 tip to singularize the cells, and then transfer 1 ml of the cell mixture to a 15-ml conical tube containing 2 ml of RPMI20 medium.
11|
Count the cells with a hemocytometer, centrifuge the cells at 200g for 5 min at room temperature, and aspirate the supernatant.
12|
Resuspend the cell pellet in albumin-containing LaSR basal medium or albumin-free RPMI/Vc/Ins medium + 5 µM Y27632 at a concentration of 100,000 cells per ml, and then seed onto a gelatin-or Synthemax-coated cell culture dish at a density of 20,000-40,000 cells per cm 2 (or a 1:6 to 1:12 split) in LaSR basal medium or 40,000-80,000 cells per cm 2 (or a 1:3 to 1:6 split) in RPMI/Vc/Ins medium. Incubate the plate at 37 °C, 5% CO 2 overnight without medium change to allow cell attachment.  crItIcal step Although albumin (BSA or human recombinant albumin) and FBS are not required here, the addition of 1% albumin or FBS may improve cell attachment and viability. Day 6 cell pellets can also be resuspended in CPC freezing medium at a density of 1 million cells per ml and frozen for long-term storage following the instructions in box 1. , aspirate the medium, add 1 ml of Accutase per well of the 12-well plate, and incubate the plate in a 37 °C, 5% CO 2 incubator for 5 min. For a quick passage without centrifugation (skipping Step 15A(ii-iv)), aspirate the Accutase, gently scrape the cells with a glass pipette into the corresponding plating medium, and seed the cells at a split ratio of 1:3 to 1:9. Alternatively, proceed to the next step.  crItIcal step Although we found that centrifugation is not necessary for cell passaging, a 5-min treatment with Accutase might dissociate the cells from the plate surface, resulting in cell loss. In that case, decrease the Accutase incubation time or use a gentler dissociating buffer (e.g., Versene). (ii) Pipette five to ten times with a P1000 tip to singularize the cells, and then transfer the 1-ml cell mixture to a 15-ml conical tube containing 2 ml of RPMI20 medium. Incubate the plate at 37 °C, 5% CO 2 overnight without medium change to allow cell attachment. This time point corresponds to day −1.  crItIcal step Although FBS or TGF-β inhibitors are not required here, the addition of 1% FBS and 0.5 µM A83-01 may improve cell attachment and viability. (ii) The next day and each day thereafter, aspirate the medium from each well of the 48-well plate, and add 400 µl per well of room-temperature LaSR basal medium with 10 ng/ml bFGF or 5 ng/ml TGF-β1 for fibroblast and SMC differentiation (Fig. 6a) , respectively. For SMC differentiation, 10 ng/ml bFGF can be used instead of 5 ng/ml TGF-β1 from days 3 to 6. Return the plate to the 37 °C, 5% CO 2 incubator. ? troublesHootInG (iii) On day 6, follow options B and C for immunostaining and flow cytometry analysis for CD90, vimentin (VIM), SMMHC, and calponin. Typical morphology of fibroblasts and SMCs and the corresponding immunostaining images are shown in Figure 6b .
? troublesHootInG Troubleshooting advice can be found in table 2.
• tIMInG Steps 1-8, cardiac progenitor differentiation with Gsk3 inhibitor and Wnt signaling inhibitor: 6 d Steps 9-14, proepicardial differentiation with Gsk3 inhibitor: 6 d
Step 15, downstream assays: variable
Step 15A, long-term maintenance of hPSC-derived epicardial cells: 4 d
Step 15B, immunostaining analysis of hPSC-derived epicardial cells: 2 d
Step 15C, flow cytometry analysis of hPSC-derived epicardial cells: 2 d
Step 15D, differentiation of hPSC-derived epicardial cells into fibroblasts and SMCs: 7 d box 1, cryostorage and thawing of cardiac progenitors and proepicardial cells: 2 d Initial cardiac progenitor purity was too low, cell seeding density was not optimal, or CHIR99021 dose and/or addition time was not optimal
Ensure that >50% of cells are Isl1 + Nkx2.5 + on day 6 or optimize initial cardiac progenitor cell seeding density in Step 9; optimize CHIR99021 concentration on days 7-9 in Step 13 15A(vi) Slow proliferation or differentiation of WT1 + cells after passage
The concentration of TGF-β inhibitor was not optimal; the initial cell seeding density was too low
Optimize TGF-β inhibitor concentration; increase the initial cell seeding density antIcIpateD results This protocol presents a rapid and efficient (>90% WT1 + cells after 2 weeks) method for the generation of self-renewing epicardial cells from multiple hPSC lines. Before starting the differentiation protocol, well-maintained hPSCs should have high levels (>95%) of pluripotency markers including Oct4 (Fig. 1) . 24 h post addition of CHIR99021, >90% of the differentiated culture should express brachyury, a mesendoderm marker (Fig. 1) . A differentiation producing <90% brachyury-positive cells might be due to poor quality of the initial hPSCs. After 5-6 d of differentiation, >50% of the cells should express cardiac-progenitor-specific markers, including Isl1 and Nkx2.5 (Fig. 1) . Cardiac progenitor differentiation of cultures with <20% of cells expressing these markers will result in a low yield of WT1 + cells. Subsequently, the CPCs will be directed toward epicardial cell fates upon Gsk3 inhibitor treatment. The cobblestone-like morphology-which is different from that of spindle-shaped cardiomyocytes-can be observed as early as day 8 ( Fig. 2;  ref. 4) . The cell number of epicardial cells is notably higher than that of cardiomyocytes derived from day 6 CPCs with the same seeding density. More than 90% of cells should express epicardial cell markers, including WT1 (Fig. 3) . The resulting WT1 + putative epicardial cells are highly proliferative upon TGF-β inhibitor treatment, and they can be passaged every 4 d, displaying epicardial characteristics for >2 months in LaSR basal medium. Epithelial cell markers such as β-catenin, ZO1, K18, and E-cadherin, as well as epicardial cell markers such as WT1, TBX18, TCF21, and ALDH1A2, should always be highly expressed during long-term maintenance (Figs. 4 and 5) .
The hPSC-derived epicardial cells can further differentiate into fibroblasts or SMCs upon bFGF or TGF-β1 treatment for 6 d. bFGF-and TGF-β1-treated cells display a fibroid spindle-like shape and a fusiform appearance typical of cultured fibroblasts and SMCs, respectively (Fig. 6) . The expression of calponin and SMMHC in TGF-β1-induced cultures further supports their SMC identity, and VIM and CD90 expression in bFGF-treated cells supports their fibroblast identity.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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